Clinical Trial

Adipose Visceral and Epicardial Risk Evaluation

Study acronym: AVERE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this procedure-based interventional study without drugs or devices is to investigate the molecular mechanisms underlying metabolically unfavorable obesity and related clinical phenotypes, in order to identify non-invasive biomarkers capable of early prediction of metabolic syndrome, type 2 diabetes mellitus, MASLD, and cardiovascular disease in adult participants without known cardiovascular or liver disease. The main questions it aims to answer are: * What is the association between epicardial and visceral fat thickness and plasma levels of low-grade inflammatory biomarkers? * How do these parameters relate to the presence of metabolic syndrome, type 2 diabetes mellitus, MASLD, and subclinical atherosclerosis? Participants will: * Undergo a comprehensive clinical evaluation, including demographic, anthropometric, and medical history data; * Complete non-invasive diagnostic assessments, including 12-lead electrocardiogram, transthoracic echocardiography, liver elastography (FibroScan), and carotid Doppler ultrasound; * Provide peripheral venous blood samples for biochemical, cellular, and molecular analyses.
Trial Details
NCT Number NCT07504679
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Subclinical Atherosclerosis
Enrollment 400 participants
Start Date 2026-05-01
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-01